Literature DB >> 6502494

Oral and intravenous pharmacokinetics of milrinone in human volunteers.

R M Stroshane, R F Koss, C E Biddlecome, C Luczkowec, J Edelson.   

Abstract

Thirty-nine healthy men received milrinone either orally or intravenously in two separate double-blind, placebo-controlled studies. The mean bioavailability, based on the area under the plasma concentration versus time curves, was 0.92. The plasma data for those subjects in the intravenous study were described by an open two-compartment model with a mean (+/- SD) apparent first-order terminal elimination rate constant (beta) of 0.86 (+/- 0.23) h-1, which corresponds to a half-life of 0.8 h. In the intravenous study, the renal clearance and total body clearance were 21.1 and 25.9 L/h, respectively. The corresponding values in the oral study were 23.8 and 29.7 L/h. Between 79.9 and 84.5% of the total doses were recovered in the urine samples taken at 0-24 h.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502494     DOI: 10.1002/jps.2600731029

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Hemodynamic response to milrinone for refractory hypoxemia during therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy.

Authors:  Adrianne R Bischoff; Sharifa Habib; Patrick J McNamara; Regan E Giesinger
Journal:  J Perinatol       Date:  2021-04-13       Impact factor: 2.521

3.  Pharmacokinetics of piroximone (MDL 19.205) in healthy volunteers.

Authors:  K D Haegele; G G Belz; T T Meinicke; P J Schechter
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

5.  Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.

Authors:  Winnie Vogt
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

6.  Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac Surgery.

Authors:  Katja M Gist; David S Cooper; Julia Wrona; Sarah Faubel; Christopher Altmann; Zhiqian Gao; Bradley S Marino; Jeffrey Alten; Kristal M Hock; Tomoyuki Mizuno; Alexander A Vinks; Melanie S Joy; Michael F Wempe; Michael R Bennett; Stuart L Goldstein
Journal:  Ther Drug Monit       Date:  2018-04       Impact factor: 3.681

7.  Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man.

Authors:  J A Scatina; D R Hicks; M Kraml; M N Cayen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

Review 8.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 9.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 10.  The pharmacokinetics and pharmacodynamics of newer inotropic agents.

Authors:  M L Rocci; H Wilson
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.